Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body…
Browsing: Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
First-in-human phase 1 trial finds the oral GLP-1/amylin co-agonist amycretin safe and well tolerated with dose-dependent gastrointestinal effects; weight and glucose changes were exploratory only. PICO summary and expert commentary.
An early-phase trial reports large but exploratory weight-loss signals for subcutaneous amycretin in overweight and obesity, with safety as the primary focus. PICO summary and expert commentary.
An Eli Lilly-sponsored indirect treatment comparison links tirzepatide 10 and 15 mg to greater weight, BMI and HbA1c reductions than semaglutide 2.4 mg in patients with type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
A phase 2b trial finds oral danuglipron produces significant weight loss in obesity but with high discontinuation from gastrointestinal side effects. PICO summary and commentary.
An exploratory analysis of two Phase 2 trials found that oral orforglipron produced placebo-adjusted reductions in cardiovascular risk biomarkers, not clinical events, in adults with type 2 diabetes or obesity. PICO summary and expert commentary.
Summary: In adults with type 2 diabetes (T2D), mycoprotein and guar gum significantly reduced postprandial glucose (PG) compared to a…
A phase 1 mechanistic study in adults with obesity found tirzepatide did not alter metabolic adaptation but increased fat oxidation and reduced calorie intake versus placebo. PICO summary and expert commentary.
A phase 1 single-ascending-dose first-in-human trial of HEC88473, a dual GLP-1/FGF21 receptor agonist, reporting tolerability and early metabolic signals in healthy and obese adults. PICO summary and expert commentary.
Once-weekly semaglutide 2.4 mg cut body weight by an estimated 8.3% more than placebo over 44 weeks in Chinese adults with overweight or obesity in the STEP 7 trial. PICO summary and expert commentary.